Compare LRHC & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRHC | XCUR |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 9.2M |
| IPO Year | 2022 | 2017 |
| Metric | LRHC | XCUR |
|---|---|---|
| Price | $0.79 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 120.6K | 15.3K |
| Earning Date | 11-18-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,507,806.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $44.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $0.94 |
| 52 Week High | $3,840.00 | $9.48 |
| Indicator | LRHC | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 15.38 | 43.50 |
| Support Level | N/A | $1.05 |
| Resistance Level | $3.08 | $1.48 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 3.20 | 50.70 |
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. The company derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.